Microsize Acquires Lonza's MicroMacinazione for Enhanced Capabilities

Microsize, a leading specialist in pharmaceutical particle size reduction, has acquired Lonza’s MicroMacinazione business unit for an undisclosed amount. This corporate acquisition signifies Microsize’s strategic move to expand its capabilities and market presence in the critical area of active pharmaceutical ingredient (API) processing.

Microsize specializes in Particle Size Reduction, Powder Classification, and Analytical Services, serving a diverse clientele from small biotechs to Big Pharma. As North America's largest independent pharmaceutical micronization business, Microsize is known for enhancing dissolution and bioavailability of APIs. Operating from FDA-inspected US facilities, it processes compounds from grams to multi-metric tons, including highly potent compounds, covering all development phases from discovery to commercial launch. Lonza’s MicroMacinazione, as suggested by its name, operates in the advanced micronization and particle processing domain, aligning directly with Microsize's core expertise.

This acquisition is strategically significant, reinforcing Microsize’s position as a premier partner for pharmaceutical development and manufacturing. The integration of MicroMacinazione is expected to enhance Microsize’s existing infrastructure, broaden its technological offerings, and potentially expand its geographic footprint or specialized service portfolio. Synergies are anticipated through combined operational efficiencies, an expanded pool of expertise in handling complex compounds like HPAPIs, and an increased capacity to support every phase of drug development.

By bringing MicroMacinazione under its umbrella, Microsize aims to solidify its leadership in particle engineering solutions. The combined entity is expected to deliver even more robust and responsive services to pharmaceutical clients, continuing its mission to improve drug efficacy and bioavailability through advanced processing techniques. This move underscores Microsize's commitment to strategic growth and its dedication to meeting the evolving needs of the global pharmaceutical industry.